HRT Financial’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

HRT Financial’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-35,800	Closed	-$273K	–	4376
2021 Q3	$273K	Buy	+35,800	New	+$304K	﹤0.01%	2473
2021 Q2	–	Sell	-16,300	Closed	-$134K	–	3752
2021 Q1	$134K	Buy	+16,300	New	+$172K	﹤0.01%	2406

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HRT Financial's SRNE Position: Q2 2021 in Review

HRT Financial sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 56,059 shares — an estimated $463K sold.

HRT Financial first reported a position in SRNE in Q3 2018 and held it in 6 quarters. The position peaked at $463K in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

HRT Financial reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
HRT Financial sold 56,059 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $463K.
HRT Financial first reported a position in Sorrento Therapeutics, Inc. in Q3 2018 and held it in 6 quarters.
HRT Financial's Sorrento Therapeutics, Inc. position peaked at $463K in Q1 2021.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on HRT Financial's 13F filing for Q2 2021, filed 16 Aug 2021.